US moves to sell gene-edited mushrooms fuel doubts over British ban on GM imports
By Robin McKie,
The Guardian
| 04. 23. 2016
Untitled Document
American regulators have allowed the cultivation and sale of two crops modified with the gene-editing technique known as Crispr. The crops – a white button mushroom and a form of corn – are the first Crispr plants to be permitted for commercial use in the US.
The move is a boost for new technology in the creation of foodstuffs, but is expected to worsen the considerable confusion in Britain over the use of gene-editing in agriculture and the importing of crops created using such technology.
A committee of European commission regulators was expected to report last month on whether gene-edited crops should be classed as genetically-modified organisms or should be freed from the severe restrictions concerning GMOs in Europe. At the last minute it announced a delay in its verdict – to the dismay of many UK scientists.
“The committee knew it would be highly controversial, no matter what decision it made, so they have kicked the issue into the long grass, and that is very damaging,” said crop scientist Professor Huw Jones of Aberystwyth university.
“Researchers...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...